Lonvia Mid-Cap World
Lonvia Mid-Cap World is a fund invested in small- and mid-cap international equities. Through a highly selective approach to securities, we invest with an asset-based vision, in companies whose business model we consider to be value-creating over the long term. The Product promotes environmental and/or social characteristics in accordance with Article 8 of the SFDR Regulation through normative and sectoral exclusions.
- SFDR : Article 8
- Risk level: 5/7
- SFDR : Article 9
- Risk level: 5/7
This fund was launched less than a year ago.
In accordance with current regulations, its performance cannot yet be published.
Main positions
| REPLIGEN CORP | 3.26 % |
| NEMETSCHEK AG | 3.11 % |
| SARTORIUS STEDIM BIOTECH | 3.06 % |
| VERTEX INC – CLASS A | 3.04 % |
| GLOBANT SA | 2.85 % |
| XVIVO PERFUSION AB | 2.74 % |
| REPLY SPA | 2.70 % |
| FORTNOX AB | 2.61 % |
| GLOBUS MEDICAL INC – A | 2.50 % |
| PTC INC | 2.49 % |
| Total | 28.36 % |
Sector breakdown
- Fund
- Benchmark
Geographical distribution
Key features
| Name | Lonvia Mid-Cap World |
| Share type | |
| ISIN code | |
| SRI Label | No |
| SFDR Rules | Article 8 |
| Eligibility | — |
| Unit launch | 18/07/2024 |
| Benchmark index | MSCI World Mid Cap Index (NR, USD) |
| Management company | LONVIA Capital |
| Managing Director | Jacques Gout-Lombard |
| Product type | UCITS |
| Legal status | SICAV under Luxembourg law |
| Custodian | CACEIS |
| Centralizing agent | CACEIS |
| Auditor | PWC |
| Subscription / redemption conditions | Daily at 12:00 CET – Unknown NAV – Settlement D+2 |
| Recommended investment period | More than 5 years |
| Minimum investment | |
| Subsequent subscriptions | 1 share |
Fees
| Entry fee (max) | |
| Exit fees (max) | 0,00% |
| Management fees (annual) | |
| Performance fees |
Each UCI may not be suitable for all investors.
The risks associated with investing in a mutual fund are described in the fund’s Prospectus and Key Information Document (DIC/DICI), which can be downloaded from this website.
Please read them carefully.